A Journal of Law, Medicine and Ethics paper examines why one-time gene therapies like Luxturna carry high prices, citing portfolio risk and smaller targeted patient groups as forces shaping incentives. It proposes spreading payments over time, bundling diagnostics with insurance, and streamlining regulation to balance innovation and access.